cognition

Hopes and Questions raised by Alzheimer’s drug Leqembi (lecanemab)

by Leave a Comment

The FDA has approved Leqem­bi, the first dis­ease-mod­i­fy­ing treat­ment for ear­ly-stage Alzheimer’s and a pre­cur­sor con­di­tion, mild cog­ni­tive impair­ment. Medicare has said it will pay for the ther­a­py. Med­ical cen­ters across the coun­try are scram­bling to final­ize poli­cies and pro­ce­dures for pro­vid­ing the med­ica­tion to patients, pos­si­bly by summer’s end or ear­ly autumn.

It’s a fraught moment, with hope run­ning high for fam­i­lies and oth­er promis­ing ther­a­pies such as donanemab on the hori­zon. Still, med­ical providers are cau­tious. “This is an impor­tant first step in devel­op­ing treat­ments for com­plex neu­rode­gen­er­a­tive dis­eases, but it’s just a first step,” said Ronald Petersen, direc­tor of the Mayo Clinic’s Alzheimer’s Dis­ease Research Cen­ter in Rochester, Min­neso­ta. [Read more…] about Hopes and Ques­tions raised by Alzheimer’s drug Leqem­bi (lecanemab)

Reading for pleasure during childhood may lead to higher brain/ cognitive development and mental well-being during adolescence

by Leave a Comment

Ear­ly child­hood is a crit­i­cal peri­od for brain devel­op­ment, which is impor­tant for boost­ing cog­ni­tion and men­tal well­be­ing. Good brain health at this age is direct­ly linked to bet­ter men­tal heath, cog­ni­tion and edu­ca­tion­al attain­ment in ado­les­cence and adult­hood. It can also pro­vide resilience in times of stress.

But, sad­ly, brain devel­op­ment can be ham­pered by pover­ty. Stud­ies have shown that ear­ly child­hood pover­ty is a risk fac­tor for low­er edu­ca­tion­al attain­ment. It is also asso­ci­at­ed with dif­fer­ences in brain struc­ture, poor­er cog­ni­tion, behav­iour­al prob­lems and men­tal health symp­toms. [Read more…] about Read­ing for plea­sure dur­ing child­hood may lead to high­er brain/ cog­ni­tive devel­op­ment and men­tal well-being dur­ing adolescence

Alto Neuroscience raises $60M (equity + credit) to help fix the “trial and error” approach to psychiatric medication

by

Alto Neu­ro­science bags $25M for four Phase II drugs (End­points News):

Anoth­er $25 mil­lion is flow­ing the way of a Cal­i­for­nia biotech attempt­ing to fix the “tri­al and error” sys­tem in neu­ro­science drug R&D.

Alto Neu­ro­science picked up the cap­i­tal from Alpha Wave Ven­tures via an exten­sion to its Series B, bring­ing total equi­ty raised to $100 mil­lion since the startup’s 2019 found­ing. [Read more…] about Alto Neu­ro­science rais­es $60M (equi­ty + cred­it) to help fix the “tri­al and error” approach to psy­chi­atric medication

Ballroom dancing can reduce aging-related brain atrophy in the hippocampus (and, more than treadmill walking!)

by

Social ball­room danc­ing can improve cog­ni­tive func­tions and reduce brain atro­phy in old­er adults who are at increased risk for Alzheimer’s dis­ease and oth­er forms of demen­tia. That’s the key find­ing of my team’s recent­ly pub­lished study in the Jour­nal of Aging and Phys­i­cal Activity.

In our study, we enrolled 25 adults over 65 years of age in either six months of twice-week­ly ball­room danc­ing class­es or six months of twice-week­ly tread­mill walk­ing class­es. None of them were engaged in for­mal danc­ing or oth­er exer­cise pro­grams. [Read more…] about Ball­room danc­ing can reduce aging-relat­ed brain atro­phy in the hip­pocam­pus (and, more than tread­mill walking!)

Taking your brain vitals: Stories from a techno-optimist inventing the future of human performance

by

Dr. Cori Lath­an, author of Invent­ing the Future: Sto­ries from a Techno-Optimist

For as long as I can remem­ber, my father loved act­ing. Into his six­ties and ear­ly sev­en­ties, he was quite active in the the­ater. He played Tartuffe in Molière’s Tartuffe, Nick Bot­tom in Shakespeare’s A Mid­sum­mer Night’s Dream, and the Old Man in Steve Martin’s Picas­so at the Lapin Agile. When he won the role of Scrooge in a local pro­duc­tion of Dickens’s A Christ­mas Car­ol, I was so excit­ed for him that I bought tick­ets way before open­ing night. But he was hav­ing trou­ble remem­ber­ing his lines. Even­tu­al­ly, the direc­tor had to let him go.

To find out what was going on, my mom and dad went to his pri­ma­ry care physi­cian, who referred him to a neu­rol­o­gist. After wait­ing a month for that appoint­ment, the neu­rol­o­gist told Dad to see a neu­ropsy­chol­o­gist, who was booked anoth­er three months out. When that appoint­ment arrived, the neu­ropsy­chol­o­gist gave him a vari­ety of cog­ni­tive tests, includ­ing writ­ten, ver­bal, and com­put­er based. After anoth­er month, the neu­rol­o­gist called us back in and told my father, “You have mild cog­ni­tive impairment.”

“No shit, Sher­lock,” I thought. “That’s why we went to see his doc­tor six months ago.” The neu­rol­o­gist then dis­cussed my father’s oth­er health issues with us, which includ­ed car­dio­vas­cu­lar dis­ease, sleep apnea, type 2 dia­betes, and by that point, depres­sion. I then had an inspi­ra­tion. “Dad, when was the last time you used your CPAP machine?” He admit­ted sheep­ish­ly, “I don’t use it. I don’t like it.” [Read more…] about Tak­ing your brain vitals: Sto­ries from a tech­no-opti­mist invent­ing the future of human performance

Study: Building cognitive reserve helps delay memory and thinking decline regardless of genetic or childhood markers

by

Source: UAB researcher David Vance

Build­ing cog­ni­tive reserve could pro­tect against mem­o­ry and think­ing decline, even with low child­hood cog­ni­tion scores (Alzheimer’s Research UK):

New research sug­gests that peo­ple who devel­op high ‘cog­ni­tive reserve’ by the time they reach 69 years old may reduce their like­li­hood of mem­o­ry and think­ing decline, even with low child­hood cog­ni­tive abil­i­ties. The study was pub­lished today in Neu­rol­o­gy, the med­ical jour­nal of the Amer­i­can Acad­e­my of Neu­rol­o­gy. [Read more…] about Study: Build­ing cog­ni­tive reserve helps delay mem­o­ry and think­ing decline regard­less of genet­ic or child­hood markers